Will Pradaxa take the lead in the NOAC treatment market by the health insurance expansion?
The insurance benefit range of the new oral anti-coagulant (NOAC) ‘Pradaxa(generic name: dabigatran)’ will be expanded from the 1st.
Through the expansion, the drug will not only have the enlarged amount of benefits, but also shorten the benefit range with ‘Xarelto (generic name: rivaroxaban)’ t...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
